Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome - PubMed (original) (raw)
. 2004 Oct 15;104(8):2247-53.
doi: 10.1182/blood-2004-02-0762. Epub 2004 Jul 13.
Deanna M Grote, Mary Stenson, Steven C Ziesmer, Thomas E Witzig, Thomas M Habermann, Brandon Harder, Kay M Ristow, Richard J Bram, Diane F Jelinek, Jane A Gross, Stephen M Ansell
Affiliations
- PMID: 15251985
- DOI: 10.1182/blood-2004-02-0762
Free article
Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome
Anne J Novak et al. Blood. 2004.
Free article
Abstract
BLyS, recently shown to be critical for survival of normal B cells, has been found to be elevated in a number of immune disease models. A role for BLyS in the survival of malignant B cells has also been revealed and we therefore sought to identify a role for BLyS and its receptors in non-Hodgkin lymphoma (NHL). We found that tumor cells from all NHL histologic subtypes expressed one or more of 3 known receptors (BCMA, TACI, and BAFF-R) for BLyS; however, the pattern of expression was variable. We provide evidence that BLyS is expressed in tumors from patients with NHL and that BLyS levels increase as tumors transform to a more aggressive phenotype. Additionally, we provide evidence that serum BLyS levels are elevated in a subgroup of patients with NHL. In patients with de novo large B-cell lymphoma, a high BLyS level correlated with a poorer median overall survival, the presence of constitutional symptoms, and elevated values of lactic dehydrogenase. When BLyS levels were correlated with response to therapy in all patients, responding patients had a significantly lower BLyS level than those with progressive disease. In summary, we found that BLyS and its receptors represent a potentially important therapeutic target in B-cell lymphoma.
Similar articles
- Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas.
Fu L, Lin-Lee YC, Pham LV, Tamayo A, Yoshimura L, Ford RJ. Fu L, et al. Blood. 2006 Jun 1;107(11):4540-8. doi: 10.1182/blood-2005-10-4042. Epub 2006 Feb 23. Blood. 2006. PMID: 16497967 Free PMC article. - BLyS and BLyS receptor expression in non-Hodgkin's lymphoma.
Briones J, Timmerman JM, Hilbert DM, Levy R. Briones J, et al. Exp Hematol. 2002 Feb;30(2):135-41. doi: 10.1016/s0301-472x(01)00774-3. Exp Hematol. 2002. PMID: 11823048 - Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL.
He B, Chadburn A, Jou E, Schattner EJ, Knowles DM, Cerutti A. He B, et al. J Immunol. 2004 Mar 1;172(5):3268-79. doi: 10.4049/jimmunol.172.5.3268. J Immunol. 2004. PMID: 14978135 - Mechanism of BLyS action in B cell immunity.
Do RK, Chen-Kiang S. Do RK, et al. Cytokine Growth Factor Rev. 2002 Feb;13(1):19-25. doi: 10.1016/s1359-6101(01)00025-9. Cytokine Growth Factor Rev. 2002. PMID: 11750877 Review. - Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies.
Shivakumar L, Ansell S. Shivakumar L, et al. Clin Lymphoma Myeloma. 2006 Sep;7(2):106-8. doi: 10.3816/CLM.2006.n.046. Clin Lymphoma Myeloma. 2006. PMID: 17026820 Review.
Cited by
- Current status of BAFF targeting immunotherapy in B-cell neoplasm.
Tagami N, Yuda J, Goto Y. Tagami N, et al. Int J Clin Oncol. 2024 Sep 2. doi: 10.1007/s10147-024-02611-2. Online ahead of print. Int J Clin Oncol. 2024. PMID: 39222149 Review. - T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting.
Anderson GSF, Chapman MA. Anderson GSF, et al. Mol Ther. 2024 Sep 4;32(9):2856-2891. doi: 10.1016/j.ymthe.2024.07.028. Epub 2024 Aug 5. Mol Ther. 2024. PMID: 39095991 Review. - Precision Medicine in Inflammatory Bowel Disease: A Spotlight on Emerging Molecular Biomarkers.
Mestrovic A, Perkovic N, Bozic D, Kumric M, Vilovic M, Bozic J. Mestrovic A, et al. Biomedicines. 2024 Jul 8;12(7):1520. doi: 10.3390/biomedicines12071520. Biomedicines. 2024. PMID: 39062093 Free PMC article. Review. - Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma.
Pang Y, Ghosh N. Pang Y, et al. Front Oncol. 2024 Apr 22;14:1396395. doi: 10.3389/fonc.2024.1396395. eCollection 2024. Front Oncol. 2024. PMID: 38711850 Free PMC article. Review. - Unraveling the Role of the NLRP3 Inflammasome in Lymphoma: Implications in Pathogenesis and Therapeutic Strategies.
Stergiou IE, Tsironis C, Papadakos SP, Tsitsilonis OE, Dimopoulos MA, Theocharis S. Stergiou IE, et al. Int J Mol Sci. 2024 Feb 17;25(4):2369. doi: 10.3390/ijms25042369. Int J Mol Sci. 2024. PMID: 38397043 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials